Switching to bedaquiline for treatment of rifampicin-resistant tuberculosis in South Africa: A retrospective cohort analysis.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31622366.
- Also identified by DOI 10.1371/journal.pone.0223308 and PMC identifier 6797261.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.
Medical subject headings
- Antitubercular Agents
- Diarylquinolines
- Drug Substitution
- Mycobacterium tuberculosis
- Tuberculosis, Multidrug-Resistant